University of California

National Institutes of Health, a Component of the US Dept. of Health & Human Services

In-Hae Kim

Bruce D Hammock

Christophe H Morisseau

Takaho Watanabe

John Newman

Paul Daniel Jones

Sung Hee Hwang

Paul Whetstone

Seung-Jin Ma

Susan E Bennett

Judith S Stern

The invention provides uses and methods for reducing nephropathy in persons with diabetes mellitus (particularly Type 2 diabetes), in persons with metabolic syndrome, in persons with triglyceride levels over 215 mg/dL, and in persons with a cholesterol level over 200 mg/dL, by administering an inhibitor of soluble epoxide hydrolase ('sEH'). Optionally, a cis-epoxyeicosantrienoic acid ('EET') can be administered with the sEH inhibitor. The invention further provides for using EETs in conjunction with one or more sEH inhibitors to reduce hypertension, and for compositions of EETs coated with a material insoluble in an acid of pH 3 but soluble in a solution with a pH of 7.4 or higher.

Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids

Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases.

Inhibitors for the soluble epoxide hydrolase

Growing community of inventors

Davis, CA, United States of America

In-Hae Kim